<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Biochemistry</strong>/<strong>Molecular</strong> <strong>Biology</strong>Visucam data (e.g. multiple regression of max MP from the Visucamon Densitometer MP at eccentricities 0.25 and 0.5 degrees had anassociated R 2 value of just 0.008 and was not statistically significant,p=0.843). Regression analysis also showed a weak relationshipbetween MP measurements from the Spectralis and Visucam devices(e.g. multiple regression of max MP from the Visucam on SpectralisMP at eccentricities 0.23 and 0.27 degrees had an associated R 2 valueof just 0.047 and was not statistically significant, p=0.348).Regression results between readings obtained on the Visucam andthose obtained on each of the other two instruments remained poorwhen orthogonal regression was used in place of ordinary leastsquares.Conclusions: MP values obtained using the Heidelberg Spectralis arecomparable to MP values obtained using the Densitometer. Incontrast, MP values obtained using the Zeiss Visucam are notcomparable with either the Densitometer or the Spectralis MPmeasuring devices. Taking cHFP as the current gold standard, theSpectralis is suitable for use in a clinical and research setting,whereas the Visucam is not.Commercial Relationships: Jessica L. Dennison, None; Jim Stack,None; Stephen Beatty, None; John M. Nolan, NoneSupport: European Research Council: CREST 281096Program Number: 3777 Poster Board Number: A0116Presentation Time: 2:45 PM - 4:30 PMA Comparison of the MacuScope and QuantifEye MacularPigment Densitometers in Two Distinct Population TypesRobert J. Donati, Elizabeth Wyles. Illinois College of Optometry,Chicago, IL.Purpose: Studies have suggested that reduced levels of macularpigment (MP) may increase risk for developing age-related maculardegeneration (AMD). There are two compact commercially availableheterochromic flicker photometry instruments that measure MP in theUSA. Previous studies revealed significant variability betweeninstruments. Our aim was to determine if the same variability wouldbe found in a young, healthy, population compared to an olderpopulation for which these instruments have more significance.Methods: Twenty young healthy adults (21-29 years old) and 28older adults (50-70 years old) with and without early signs of AMDwere recruited from the Illinois Eye Institute patient base. Macularpigment optical density (MPOD) was measured using the MacuScopeand QuantifEye. Data was collected for each patient in one session. Asingle, but different operator collected data for each of the patientpopulations. Two measurements per eye were taken on eachinstrument and each eye was used as a separate data point. If thedifference was greater than 0.04 absorbance units between twomeasurements on a single instrument, a third measurement was taken.Invalid readings were excluded. Paired t-tests and ANOVA weredone to compare the statistical significance of the results from bothinstruments and age groups. Bland-Altman plots were done for anadded comparison.Results: Mean MPOD for the combined age groups was 0.335 ±0.137 for the MacuScope (n=83) and 0.350 ± 0.186 for theQuantifEye (n=83). There was no significant difference between theMPOD means. The mean standard deviation of each subject’s MPODreadings was 0.0943 ± 0.0822 for the MacuScope (n=87) and 0.0508± 0.0496 for the QuantifEye (n=86). There is a significant differencebetween the two instruments (p
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Biochemistry</strong>/<strong>Molecular</strong> <strong>Biology</strong>Nicole K. Scripsema 1, 3 , Nishit Shah 2 , Patricia Garcia 1 , DavidWarrow 1 , Karen Tobias 2 , Gennady Landa 1, 3 , Richard B. Rosen 1, 3 .1 The Retina Center, The New York Eye and Ear Infirmary, NewYork, NY; 2 The Einhorn Clinical Research Center, The New YorkEye and Ear Infirmary, New York, NY; 3 Ophthalmology, New YorkMedical College, Valhalla, NY.Purpose: Previously, our group reported objective evidence of lowermacular pigment density (MP) levels in patients with Type IIDiabetes (DM) with early retinopathy, which inversely correlatedwith their hemoglobin A1c. The purpose of this study was todetermine if lutein (L) or zeaxanthin (Z) supplementation couldincrease levels of MP in a similar population.Methods: Patients with DM with early retinopathy were enrolled inthe clinical trial. Each was assigned to one of four supplementationformulations containing different doses of L or Z (ZeaVision,Chesterfield, MO). Patients were examined at baseline, 1 month, 3months, 6 months, and 1 year. At each visit, patients were imagedtwo objective techniques for measuring MP. Total MPOD at 1.0degree from the fovea was measured with a modified scanning laserophthalmoscope (HRA Heidelberg Retinal Angiograph, Heidelberg,Germany). Individual LOD and ZOD at 1.0 degee from the foveawere measured with the Macular Pigment Reflectometer (MPR,Maastricht, Netherlands). Paired t-tests were used to compare meanoptical densities. We are reporting preliminary 6 month data.Results: 24 eyes of 13 patients were included. Two eyes wereexcluded due to inadequate image analysis. 38% were male. Meanage was 61.0±8.2 yrs. 46% were Hispanic, 24% Asian, 15%Caucasian, 15% African American. All patients had Type II DM withearly retinopathy. Mean duration of DM was 21.3±11.2 yrs and meanHbA1c was 7.4±1.4 mg/dL. Changes in mean MPOD, ZOD, andLOD are shown in Table 1. Each parameter showed significantincreases from baseline after 1-3 months of supplementation.Conclusions: These results suggest that in Type II DM patients withearly retinopathy, supplementation of L or Z can increase MP levelsin the parafoveal area. This may prevent the onset of maculopathy bymaintaining or restoring the oxidant-antioxidant balance in conditionassociated with increased levels of oxidative stress in the retina.Commercial Relationships: Nicole K. Scripsema, None; NishitShah, None; Patricia Garcia, None; David Warrow, None; KarenTobias, None; Gennady Landa, None; Richard B. Rosen, Opko-OTI (C), Optos (C), Clarity (C), OD-OS (C), Topcon (R), Zeavision(F), Genetech (F), Optovue (C)Support: The Bendheim-Lowenstein Retina Fund of the New YorkEye and Ear InfirmaryClinical Trial: NYEE0936France; 4 Unité de Soutien Méthodologique à la Recherche (USMR),CHU de Bordeaux, Bordeaux, France; 5 Service d’Ophtalmologie,CHU de Dijon, Dijon, France.Purpose: The macular pigment may protect against age-relatedmacular degeneration (AMD). It is formed of lutein (L) andzeaxanthin (Z), two dietary carotenoids. Some studies have suggestedthat omega 3 fatty acids may help increasing macular pigmentdensity. We performed a randomized trial testing the efficacy of adietary supplement containing L, Z, omega 3 fatty acids andantioxidants for increasing macular pigment density in subjects athigh genetic risk for AMD.Methods: The Limpia Study is a double-blind, placebo controlled,prospective randomized clinical trial performed in 120 subjects withat least one parent affected by neovascular AMD. To be included,subjects had to be aged 40-70 years, have best-corrected visual acuity(BCVA) greater than 20/25, be free of late AMD and other major eyeconditions (severe glaucoma, high myopia, severe retinal disease,cataract surgery…). Included subjects were randomly assigned toreceive Nutrof® Total (2 gels/day, representing lutein 10 mg/day,zeaxanthin 2 mg/day, long chain omega 3 fatty acids 540 mg/day,vitamin C 180 mg/day, vitamin E 30 mg/day, zinc 15 mg/day, copper1 mg/day and resveratrol 1 mg/day ) or placebo for 6 months (Figure1). The primary outcome was the variation of macular pigmentoptical density (MPOD). Secondary outcomes included visualfunction, nutritional biomarkers and cognitive function. MPOD wasmeasured by two methods (modified Heidelberg Retinal Analyzer,Heidelberg, Germany and Visucam 200 MPD, Carl Zeiss Meditec,Germany) every 3 months during one year. This allows studying thevariation of macular pigment density during the 6 monthsupplementationphase, and during 6 months after the cessation of thesupplementation.Results: 120 subjects were included from December 2010 to January2012. Mean age was 56.7 years and 71.7 % were women. The motherof 97 subjects (80.8 %) was affected by AMD, while in only 25subjects (20.8 %) the father was affected. At baseline, mean MPODwithin 0.51°, measured with the modified HRA method, was 0.5(standard deviation 0.2). Maximal MPOD, measured with Visucam,was 0.4 (standard deviation 0.1).Conclusions: Middle-aged subjects with at least one parent affectedby AMD appear to have similar macular pigment density as observedin the general population.Commercial Relationships: Jean-Francois Korobelnik, Alcon (C),Allergan (C), Bayer (C), Carl Zeiss Meditec (C), Novartis (C), Thea(F); Marie-Noelle Delyfer, Thea Laboratories (F); Marie B.Rougier, THEA (C), Bausch&Lomb (C), Allergan (C), Kemin (C);Hélène Savel, None; Geneviève Chêne, None; Cecile Delcourt,Laboratoires Théa (F), Novartis (C), Bausch+Lomb (C); CatherineP. Garcher, Alcon (C), Allergan (C), Baush and Lomb (C), BayerPharma (C), Novartis (C), Laboratoire Théa (C)Support: Grants from Laboratoires Thea and Carl Zeiss MeditecClinical Trial: NCT01269697Program Number: 3780 Poster Board Number: A0119Presentation Time: 2:45 PM - 4:30 PMA randomized trial of supplementation with lutein, zeaxanthin,omega 3 fatty acids and antioxidants for increasing macularpigment optical density in high-risk subjects: the LIMPIA StudyJean-Francois Korobelnik 1, 2 , Marie-Noelle Delyfer 1, 2 , Marie B.Rougier 1 , Hélène Savel 4 , Geneviève Chêne 4 , Cecile Delcourt 2, 3 ,Catherine P. Garcher 5 . 1 Service d'Ophtalmologie, Hopital Pellegrin,Bordeaux, France; 2 Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France; 3 INSERM, ISPED,Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux,Program Number: 3781 Poster Board Number: A0120Presentation Time: 2:45 PM - 4:30 PMComparison of macular pigment optical density measured byautofluorescence and reflectometry: the LIMPIA StudyCatherine P. Garcher 1, 2 , Marie-Noelle Delyfer 3, 4 , Marie B. Rougier 3 ,Hélène Savel 6 , Geneviève Chêne 6 , Cecile Delcourt 5, 6 , Jean-FrancoisKorobelnik 3, 4 . 1 Ophthalmology, University Hospital, Dijon, France;2 Eye and Nutrition Research Group, UMR CSGA-1324 INRA-6265CNRS-Université de Bourgogne-AgroSup, Dijon, Dijon, France;3 Ophthalmology, CHU Bordeaux, Bordeaux, France; 4 Univ.Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.